Anonymousabout 5 hours ago
A growing body of clinical evidence from landmark trials — SELECT, FLOW, STEP-HFpEF, and SURMOUNT-OSA — indicates that GLP-1 receptor agonists like semaglutide and tirzepatide deliver substantial cardiovascular, kidney, and metabolic benefits even in patients who lose little or no weight. A 2025 Lancet analysis of the SELECT trial estimated that roughly two-thirds of the observed reduction in major cardiovascular events was unrelated to weight loss, raising questions about whether current insurance coverage frameworks that gate access on BMI thresholds and weight-loss response are leaving millions of patients unable to access drugs that could protect their hearts and kidneys.